DESIGN, SYNTHESIS, MOLECULAR DOCKING, AND BIOLOGICAL EVALUATION OF PYRAZOLE 1-CARBOTHIAMIDE INCORPORATED ISOXAZOLE DERIVATIVES
Objectives: Novel isoxazole incorporated pyrazole carbothiamide 5 (a-r) was designed and synthesized, docked and evaluated for anticancer activity Michigan Cancer Foundation-7 (MCF-7), and breast cancer cell lines.
Materials and Methods: Designed compounds were synthesized by the condensation of 1-(5-methyl-3-(4-nitrophenyl) isoxazole-4-yl) -3-(substitutedphenyl) prop-2-en-1-one (4) with thiosemicarbazides and substituted thiosemicarbazides to give the target molecules 5 (a-r). To predict the affinity and activity of the ligand molecule, the docking program Accelrys Discovery Studio 2.1 was employed to generate different bioactive binding poses of designing molecules at the active site of human Dihydrofolate Reductase (DHFR) (PDB ID: 1KMS). All the synthesized compounds were characterized based on the spectral and elemental analysis data. Antiproliferative activity was performed against MCF-7 breast cancer cell lines.
Results: All the synthesized compounds showed the characteristic peaks in Fourier-transform infrared,1H C13NMR, and mass spectral analysis. During docking, all the synthesized compounds 5 (a-r) exhibited higher fitness scores with minimum three bonding interaction with the active site human DHFR (PDB ID: 1KMS). In the MTT assay based on MCF-7 breast cancer cell lines, most of the compounds exhibited significant activity. In the antiproliferative assay against MCF-7 cell lines, most of the compounds exhibited potent activity with IC50 values in micromolar concentrations. Compounds 5a, 5b, 5f, 5h, and 5k have exhibited significant anticancer activity.
Conclusions: The derivatives were synthesized in quantitative yields. New derivatives possess the antiproliferative activity and antitubercular activity.
2. Srivastava V, Kumar A, Mishra BN, Siddiqi MI. Molecular docking studies on DMDP derivatives as human DHFR inhibitors. Bioinformation 2008;3:180-8.
3. Hagner N, Joerger M. Cancer chemotherapy: Targeting folic acid synthesis. Cancer Manag Res 2010;2:293-301.
4. Arooj M, Sakkiah S, Cao Gp, Lee KW. An innovative strategy for dual inhibitor design and its application in dual inhibition of human thymidylate synthase and dihydrofolate reductase enzymes. PLoS One 2013;8:e60470.
5. El-Feky SA, Abd El-Samii ZK, Osman NA, Lashine J, Kamel MA, Thabet HKh, et al. Synthesis, molecular docking and anti-inflammatory screening of novel quinoline incorporated pyrazole derivatives using the pfitzinger reaction II. Bioorg Chem 2015;58:104-16.
6. Rangaswamy J, Kumar HV, Harini ST, Naik N. Synthesis of benzofuran based 1,3,5-substituted pyrazole derivatives: As a new class of potent antioxidants and antimicrobials a novel accost to amend biocompatibility. Bioorg Med Chem Lett 2012;22:4773-7.
7. Michon V, du Penhoat CH, Tombret F, Gillardin JM, Lepage F, Berthon L. Preparation, structural analysis and anticonvulsant activity of 3-and 5-aminopyrazole N-benzoyl derivatives. Eur J Med Chem 1995;30:147-55.
8. Shi JB, Tang WJ, Qi XB, Li R, Liu XH. Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: Synthesis and anticancer activity. Eur J Med Chem 2015;90:889-96.
9. Gurunanjappa P, Nagamallu R, Kariyappa AK. synthesis and antimicrobial activity of novel fused pyrazoles. Int J Pharm Pharm Sci 2014;7:379-81.
10. Khunt RC, Khedkar VM, Chawda RS, Chauhan NA, Parikh AR, Coutinho EC, et al. Synthesis, antitubercular evaluation and 3D-QSAR study of N-phenyl-3-(4-fluorophenyl)-4-substituted pyrazole derivatives. Bioorg Med Chem Lett 2012;22:666-78.
11. el-Sabbagh OI, Baraka MM, Ibrahim SM, Pannecouque C, Andrei G, Snoeck R, et al. Synthesis and antiviral activity of new pyrazole and thiazole derivatives. Eur J Med Chem 2009;44:3746-53.
12. Ansari A, Ali A, Asif M. Biologically active pyrazole derivatives. New J Chem 2017;41:16-41.
13. Rajput SS, Patel SN, Jadhav NB. Isoxazole a basic aromatic heterocycle: Synthesis, reactivity and biological activity. Int J Chem Tech Res 2015;8:297-17.
14. Zimecki M, B?chor U, M?czy?ski M. Isoxazole derivatives as regulators of immune functions. Molecules 2018;23:2724.
15. Radhika T, Sravanthi S, Babu VH, Reddy BM. Synthesis, Biological evaluation and molecular docking studies of isoxazole synchronized quinazolinone derivatives. J Pharm Res 2017;11:895-2.
16. Loh B, Vozzolo L, Mok BJ, Lee CC, Fitzmaurice RJ, Caddick S, et al. Inhibition of HIV-1 replication by isoxazolidine and isoxazole sulfonamides. Chem Biol Drug Des 2010;75:461-74.
17. Panda SS, Chowdary PV, Jayashree BS. Synthesis, antiinflammatory and antibacterial activity of novel indolyl-isoxazoles. Indian J Pharm Sci 2009;71:684-7.
18. Durgamma S, Reddy PR, Padmavathi V, Padmaja A. Synthesis and antioxidant activity of amido-linked benzoxazolyl/benzothiazolyl/ benzimidazolyl-pyrazoles and isoxazoles. J Heterocycl Chem 2016;53:738-47.
19. Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M. Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother 2005;55:483-8.
20. Basha SS, Divya K, Padmaja A, Padmavathi V. Synthesis and antimicrobial activity of thiazolyl pyrazoles and isoxazoles. Res Chem Int 2015;41:10067-83.
21. Dabholkar VV, Ansari FY. Synthesis and characterization of selected fused isoxazole and pyrazole derivatives and their antimicrobial activity. J Serbian Chem Soc 2009;74:1219-28.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.